Technical Analysis for TRIL - Trillium Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical TRIL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | -6.80% | |
| Fell Below 20 DMA | Bearish | 0.29% | |
| BB Squeeze Ended | Range Expansion | 0.29% | |
| Down 3 Days in a Row | Weakness | 0.29% | |
| 20 DMA Support | Bullish | -3.96% | |
| Bollinger Band Squeeze | Range Contraction | -3.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 1 day ago |
| Down 1 ATR | 1 day ago |
| Down 5% | 1 day ago |
| Fell Below 10 DMA | 1 day ago |
| Fell Below 20 DMA | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2019
Trillium Therapeutics Inc. is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company has two premier preclinical
programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune system.
SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule
that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other
malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the
activity of CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors.
For more information visit: www.trilliumtherapeutics.com
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Treatment Of Cancer Monoclonal Antibody Cancer Immunotherapy Tumor Acute Myeloid Leukemia Antibody Drug Conjugates Fusion Protein Cancer Research Tumor Cell Cd20 CD47
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immunology Solid Tumors Immune System Treatment Of Cancer Monoclonal Antibody Cancer Immunotherapy Tumor Acute Myeloid Leukemia Antibody Drug Conjugates Fusion Protein Cancer Research Tumor Cell Cd20 CD47
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.96 |
| 52 Week Low | 4.05 |
| Average Volume | 1,312,281 |
| 200-Day Moving Average | 12.10 |
| 50-Day Moving Average | 11.63 |
| 20-Day Moving Average | 10.71 |
| 10-Day Moving Average | 10.61 |
| Average True Range | 0.73 |
| ADX | 24.08 |
| +DI | 17.55 |
| -DI | 23.53 |
| Chandelier Exit (Long, 3 ATRs ) | 10.02 |
| Chandelier Exit (Short, 3 ATRs ) | 11.73 |
| Upper Bollinger Band | 11.66 |
| Lower Bollinger Band | 9.77 |
| Percent B (%b) | 0.34 |
| BandWidth | 17.60 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.33 |
| MACD Histogram | 0.0954 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.58 | ||||
| Resistance 3 (R3) | 11.69 | 11.41 | 11.38 | ||
| Resistance 2 (R2) | 11.41 | 11.12 | 11.36 | 11.32 | |
| Resistance 1 (R1) | 10.92 | 10.94 | 10.78 | 10.81 | 11.25 |
| Pivot Point | 10.64 | 10.64 | 10.58 | 10.59 | 10.64 |
| Support 1 (S1) | 10.15 | 10.35 | 10.01 | 10.04 | 9.59 |
| Support 2 (S2) | 9.87 | 10.17 | 9.82 | 9.52 | |
| Support 3 (S3) | 9.38 | 9.87 | 9.46 | ||
| Support 4 (S4) | 9.27 |
